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Abstract 
The purpose of this study was to investigate distortion product 
otoacoustic emissions (DPOAEs) in young normal-hearing children 
with sickle cell disease (SCD). It was hypothesized that the 
prevalence of DPOAEs and response amplitudes would be lower than 
those in children with normal hemoglobin due to suspected 
compromised cochlear function as a result of vaso-occlusive 
events characteristic of SCD. Twenty African-American children 
with SCD and 15 African-American children with normal hemoglobin 
participated. Distortion product OAEs were evoked by thirteen 
primary tone pairs with f2 frequencies ranging from 1000 to 4500 
Hz. The primary tones were presented at and L1 and L2 levels of 
70 and 60 dB SPL (high) and 50 and 40 dB SPL (low), 
respectively. The findings of this study were completely 
unexpected and contrary to our original hypotheses. The 
likelihood of detecting a DPOAE response was not related to the 
clinical status of the children. Distortion product OAE 
amplitudes were significantly larger for children with SCD (p = 
.01). 
 
Educational Objectives: After completing this article the reader 
will (1) have a basic knowledge of the audiometric complications 
of sickle cell disease and (2) appreciate the differences in 
DPOAEs between young normal-hearing children with sickle cell 
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disease and young normal-hearing children with normal 
hemoglobin. 
 
KEY WORDS: Audiology, Auditory Thresholds, Otoacoustic 
Emissions, Sickle Cell Disease.
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Sickle cell disease (SCD) is a hereditary genetically 
determined hemolytic disorder. Of all the hemaglobinopathies, 
SCD is the most prevalent (Forman-Franco, Karayalcin, Mandel, & 
Abramson, 1982; Marcus & Lee, 1976). The disease is expressed in 
descendants of populations from geographical areas with a high 
incidence of malaria such as Africa, the Mediterranean, and 
southeast Asia. Sickle cell disease is characterized by 
arthralgia, acute attacks of abdominal pain, and ulcerations of 
the lower extremities (Danish & Giordano, 1992; Ranney, 1992; 
Song, 1971). Sickle shaped erythrocytes are caused by the 
presence of hemoglobin S. In normal healthy individuals, 
hemoglobin is genetically coded HbA. In people with SCD, these 
normal genes have been replaced by a mutated gene, coded for 
hemoglobin S (i.e., HbSS). 
This presence of hemoglobin S has several consequences. 
First, sickled cells die more rapidly than normal disc shaped 
red blood cells (c.f. 16 vs. 120 days). Second, sickled red 
blood cells do not reproduce as rapidly as normal red blood 
cells, causing a depletion in the number of red blood cells 
present in the body. Finally, because of their distorted shape 
and inherent stiffness, sickled cells have difficulty passing 
through small blood vessels. Inadequate oxygenation of the blood 
and, ultimately, organs throughout the body results. When the 
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oxygen reaches a certain level, an increase in the sickling of 
the blood cells occurs, precipitating "crisis" episodes and 
causing the individual with SCD intense pain and organ 
malfunction (Ranney, 1992; Song, 1971). 
It has been reported that the prevalence of hearing loss is 
greater among people with SCD than in the general population. 
The prevalence of hearing loss has been reported to range from 
approximately 12% to 41% in the sickle cell population (Adams & 
Benson, 1991; Ajulo, Osiname, & Myatt, 1993; Ashoor & Al-Awamy, 
1985; Atsina & Ankra-Badu, 1988; Crawford et al., 1991; Forman-
Franco et al., 1982; Friedman, Luban, Herrar, & Williams, 1980; 
Gentry, Davis, & Dancer, 1997; Odetoyinbo & Adekile, 1987; Todd, 
Serjeant, & Larson, 1973). The etiology of hearing losses in 
individuals with SCD involves conductive (De Virgiliis et al., 
1979; Hazell & Modell, 1976), cochlear (Berry, 1975; Elwamy & 
Kamel, 1988; Gould et al., 1991; Hotaling, Hillstrom, & Bazell, 
1989; Schreibstein, MacDonald, Cox, McMahon, & Bloom, 1997; 
Serjeant, Norman, & Todd, 1975; Sharp & Orchik, 1978; Tavin, 
Rubin, & Camacho, 1993;) and central (Orchik & Dunn, 1977; Sharp 
& Orchik, 1978) processes. 
There is, however, a paucity of organized information 
concerning the manifestation of neuro-otologic and audiologic 
complications of SCD both in its early and later stages. Given 
the histopathology findings (Morganstein & Manace, 1969; Pollack 
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& Lipscombe, 1979) and audiometric data (Urban, 1973; Wilimas, 
McHaney, Presbury, Dahl, & Wang, 1988), several investigators 
(Forman-Franco et al., 1982; Friedman et al., 1980; O'Keeffe & 
Maw, 1991) have expressed surprise that the hearing of 
individuals with SCD is not more affected than reported in the 
literature. Friedman and her colleagues (1980) suggested the 
possibility that cochlear damage may be present but not apparent 
from pure tone threshold results. 
Because SCD is characterized by vaso-occlusive events 
occurring in a range from microvasculature to large muscular 
arteries, one would suspect that cochlear function would be 
particularly vulnerable, considering the delicate nature of 
cochlear vasculature (Haupt, Scheibe, & Ludwig, 1993; Scheibe, 
Haupt, & Baumgärtl, 1997; Slepecky, 1996). As a growing body of 
evidence demonstrates the greater sensitivity of otoacoustic 
emissions (OAEs) over psychoacoustic and/or standard behavioural 
testing in the detection of early or subclinical cochlear damage 
(e.g., Lonsbury-Martin, McCoy, Whitehead, & Martin, 1993; 
Prieve, Fitzgerald, Schulte, & Kemp, 1997; Schweinfurth, Cacace, 
& Parnes, 1997), an investigation exploring the otoacoustic 
emissions in individuals with SCD appeared warranted. To the 
best of our knowledge, there are no published reports of this to 
date.  
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The purpose of this study was to investigate OAEs in 
individuals with SCD. Specifically, we chose to evaluate 
distortion product otoacoustic emissions (DPOAEs) in young 
normal hearing African-American children with SCD. It was felt 
that DPOAEs may reveal early or subclinical cochlear damage as a 
result of vaso-occlusive events characteristic of the disease. 
It was hypothesized that the prevalence of DPOAEs in the 
children with SCD would be lower than that of the children with 
normal hemoglobin. It was also hypothesized that any DPOAEs 
observed in children with SCD would be lower in amplitude than 
those displayed by children with normal hemoglobin due to the 
possibility of compromised cochlear function. 
Method 
Participants 
Twenty African-American children with homozygous (HbSS) 
SCD, ranging in age from 6 to 13 years (M = 8.9 years, SD = 2.2; 
11 males and 9 females) participated. They were selected from 
the East Carolina University School of Medicine Sickle Cell 
Clinic at Pitt County Memorial Hospital, Greenville, NC. An age- 
and gender-matched control group (M = 8.4 years, SD = 2.1; 6 
males and 9 females) of 15 African-American children with normal 
hemoglobin also participated. All participants presented with 
normal otoscopy, normal middle ear function (American Speech-
Language-Hearing Association, 1990) and normal hearing 
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sensitivity defined as having pure-tone thresholds at octave 
frequencies from 500 to 8000 Hz of ≤ 20 dB HL (American National 
Standards Institute, 1996). Average pure tone thresholds, for 
both groups are presented in Table 1. 
Apparatus 
Distortion product OAEs were measured with a Grason-Stadler 
GSI-60 DPOAE SYSTEM (Revision 4.2.0) interfaced with a personal 
computer (Compaq Model Deskpro 2000). Primary tones with an f2/f1 
ratio of 1.22 were used to evoke DPOAEs. Recordings were 
obtained from 1000 to 4500 Hz at f2 frequencies of 1078, 1218, 
1359, 1546, 1734, 1921, 2156, 2437, 2718, 3093, 3468, 3890, and 
4359 Hz. These frequencies were selected because DPOAE test 
performance is best in the mid to high frequency range and 
poorest in the lower and higher frequencies (Gaskill & Brown, 
1990; Gorga et al., 1993a, Gorga et al., 1993b; Kimberly, 
Hernandi, Lee, & Brown, 1997). Two levels of primaries were 
employed to evoke the DPOAEs. For the "high-level" condition, L1 
and L2 were set at 70 and 60 dB SPL, respectively. In the "low-
level" condition, L1 and L2 were set at 50 and 40 dB SPL, 
respectively. Distortion product OAEs were measured using a 
sequential signal presentation. Averaging the DPOAE data was 
done in the time domain. Ten averages were obtained on each data 
point. Sampling rate was 24000 Hz for all conditions. 
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Frame rejection occurred if the ambient noise level 
exceeded 30 dB SPL or if L1 or L2 was out of tolerance by +/-5 
dB. Test termination occurred if the test time exceeded 32 
seconds or 1500 frames, if frame rejection occurred 50 times due 
to excessive ambient noise, or if frame rejection occurred 20 
times due to L1 or L2 being out of tolerance for at least 20 
frames. The test was accepted when at least 10 frames were 
averaged, the average noise level was less than -6 dB SPL, and 
either the DPOAE was 10 dB above the noise floor or the absolute 
noise level was less than 
-12 dB SPL. 
Procedure 
All testing was conducted in either a double wall sound-
treated audiometric suite (Industrial Acoustics Corporation) 
meeting specifications for permissible ambient noise (American 
National Standards Institute, 1991) or a quiet clinical 
examination room. Typical background noise in the clinical 
examination room was less than 30 dBA. Participants sat quietly 
while a probe assembly was placed securely in the ear canal. 
With the probe in place the test was initiated via the computer. 
Both ears of all participants were tested. 
Distortion product OAEs were estimated as the amplitude in 
the frequency bin for the cubic distortion product 2f1- f2. Noise 
estimates were obtained from the average amplitude of the three 
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frequency bins on either side of the cubic distortion product 
bin (Gorga et al., 1997). The noise floor was set at -6 dB SPL. 
A DPOAE was determined to be present if its amplitude exceeded 
the noise floor by at least 3 dB. 
Results 
Only those DPOAEs with amplitudes greater than the noise 
floor by at least 3 dB were included in the analyses. 
Consequently, DPOAE data were not available for all evoking 
primary pairs for all participants. Table 2 displays the 
percentage of observed DPOAEs observed as a function of group, 
ear, primary tone level and f2 frequency.  
A logistic regression analysis was undertaken to ascertain 
which independent variables were significant predictors of the 
presence or absence of a DPOAE response (i.e., binary dependent 
variable). The analysis was performed using SPSS LOGISTIC 
REGRESSION (Version 8.0.0). Predictor variables of group, ear, 
level and f2 frequency were fit in the logistic regression model. 
The analysis revealed that ear, Wald statistic (1) = 4.51, p = 
.03, and level, Wald statistic (1) = 4.51, p < .0001, were 
statistically significant predictors of a DPOAE response. Group, 
Wald statistic (1) = 2.3, p = .13, and frequency, Wald statistic 
(1) = .83, p = .36, were not statistically significant 
predictors of a DPOAE response.  In other words, the presence of 
a DPOAE response was more likely to be observed in a 
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participant’s right ear and in the high L1/L2 condition. The 
likelihood of a DPOAE response was not dependent on group or 
frequency. 
Mean DPOAE amplitudes as a function of f2 primary frequency 
for each group for the low-level and high-level conditions are 
presented in Figures 1 and 2, respectively. Figures 3 and 4 
display individual DPOAE amplitudes for the children with SCD 
relative to the tenth and ninetieth percentiles of the DPOAE 
amplitudes from the children with the normal hemoglobin, for the 
high and low primary tone levels, respectively. A four-factor 
mixed analysis of variance (ANOVA) was undertaken to investigate 
differences in mean DPOAE amplitudes as a function of group, 
ear, primary tone level and f2 frequency. This and the following 
ANOVA were performed using the SAS System PROC MIXED (SAS 
Institute, Version 6.12). This procedure is appropriate for data 
sets with missing data, as long as the missing data are random 
(Littell, Milliken, Stroup, & Wolfinger, 1996). The results of 
the analysis are presented in Table 3. As is evident in Table 3, 
statistically significant main effects were found for group, 
frequency and level (p < .05). That is, DPOAE amplitudes were 
significantly larger for children with SCD, larger at the higher 
stimulus level, and larger for lower f2 primary frequencies. The 
findings of significant main effects of frequency and level on 
DPOAE amplitudes were completely expected. Four statistically 
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significant interactions also occurred (p < .05). These were 
group by level, frequency by level, ear by level, and group by 
frequency. Although these interactions attained statistical 
significance they are not deemed to be clinically significant. 
All other main effects and interactions were not statistically 
significant (p > .05). 
A four-factor mixed ANOVA was also undertaken to examine 
differences in mean noise amplitude as a function of group, ear, 
primary tone level and f2 frequency. The analysis revealed no 
statistically significant differences for group [F (1, 15) = 
1.79, p = .20,η2 = .11, φ = .24 at α = .05] or ear [F (1, 15) = 
0.006, Greenhouse-Geisser p = .94,η2 = .00, φ = .051 at α = .05]. 
Significant main effects of frequency [F (12, 180) = 23.52, 
Greenhouse-Geisser p < .0001,η2 = .61] and level [F (1, 15) = 
33.79, Greenhouse-Geisser p < .0001,η2 = .69] were found. All 
interactions of main effects were not statistically significant 
(p > .05). The significant main effect of frequency reflected, 
as anticipated, the fact that the noise floor decreased with 
increasing frequency. During DPOAE recording, the noise floor 
evidenced with the high primary tone level was significantly 
louder than the noise floor with low primary tone level by 
approximately 1.6 dB (c.f. –8.1 and –9.7 dB SPL, respectively). 
It is believed that this finding reflected the test acceptance 
criterion of averaging DPOAE responses which were 10 dB above 
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the noise floor (i.e., more robust responses at the high primary 
tone level afforded a higher noise floor). 
Discussion 
The findings of this study indicated that children with SCD 
have larger DPOAE amplitudes than children with normal 
hemoglobin and that the prevalence of DPOAEs does not differ 
between the two groups. These results were completely unexpected 
and contrary to our original hypotheses. It was hypothesized 
that any DPOAEs observed in the children with SCD would be 
diminished in amplitude and the prevalence of DPOAEs would be 
lower than that of the children with normal hemoglobin due to 
suspected compromised cochlear function resulting from the vaso-
occlusive nature of the disease. It is important first to point 
out that the DPOAE findings in the control sample were 
consistent with previous findings of DPOAE amplitudes in normal-
hearing children (Owens, McCoy, Lonsbury-Martin, & Martin, 1993; 
Prieve et al., 1997).  
At first glance the findings that children with SCD have 
larger DPOAE amplitudes than children with normal hemoglobin are 
difficult to interpret. Considering contemporary models of OAE 
generation (e.g., Kemp, 1980; 1997), several possibilities for 
these findings may be offered. First, some dysfunction or 
reduction in the efferent suppression of outer hair cell 
activity may be present in the children with SCD. This could be 
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a consequence of aberrant medial olivocochlear neuron function 
or a disruption of olivocochlear efferent transmitter function. 
This is highly speculative, and there is no evidence at this 
time to indicate that this is the case in individuals with SCD. 
Second, outer hair cells of children with SCD may be hyper-
responsive and the mechanism does not involve efferent system 
dysfunction. To the best of our knowledge, there is no research 
to provide insight into this explanation. Third, children with 
SCD may be on medication regimes that are in some way mediating 
hyper-responsive activity in outer hair cell function. Some 
pharmacological agents are known to prevent the inhibition of 
the OAE response (e.g., Chen, Skellett, Fallon, & Bobbin, 1998; 
Kujawa, Glattke, Fallon, & Bobbin, 1994). There is also evidence 
of enhancement of OAEs following drug administration or insult 
to the olivocochlear efferent system in some individuals 
(Berlin, Hood, Cecola, Jackson, & Szabo, 1993; Berlin, Hood, 
Hurley, & Wen, 1994). A test of this hypothesis would involve an 
investigation of contralateral suppression of OAEs in children 
with SCD. If the mechanism involves a reduction of efferent 
system input, it is logical to assume that a stimulus which 
would normally suppress OAEs would have less, if any, effect on 
DPOAE suppression in people with SCD. Further, although both 
groups of children presented with clinically defined normal 
middle ear function, some undetected differences could have 
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existed. For example, children with SCD may have more efficient 
backward transmission than children with normal hemoglobin, 
contributing to greater amplitude DPOAEs (Kemp, 1980; Margolis & 
Trine, 1997). Finally, one could speculate that larger OAE 
amplitudes in children with SCD might be a consequence of 
smaller ear canals relative to those in children with normal 
hemoglobin. Although we are not aware of any data reporting 
smaller ear canal volumes, it is well documented that children 
with SCD are typically smaller than normally developed age-
matched children (Ebomoyi, Adedoyin, & Ogunlesi, 1989; 
Henderson, Saavedra, & Dover, 1994; Phebus, Gloninger, & Maciak, 
1984; Platt, Rosenstock, & Espeland, 1984; Stevens, Maude, 
Cupidore, Jackson, Hayes, & Serjeant, 1986). Smaller ear canal 
volumes have been hypothesized to account for larger OAE 
amplitudes (Norton & Widen, 1990). Further investigations are 
needed to address these speculations. 
The clinical applications of these data need to be further 
explored, as well. Because the literature supports decreased 
hearing sensitivity in children with SCD (Gentry et al., 1997), 
one must address what mechanism(s) account(s) for the time 
course and change in hearing sensitivity that eventually plagues 
many of these individuals. If normal-hearing children with SCD 
do have better OAEs than their counterparts with normal 
hemoglobin, several questions must be addressed. More thorough 
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attention in case history addressing neurological complications, 
number of crises, time since last crisis, medication regimes, 
intravenous treatments, and transfusion history may provide 
significant insight into the etiology of hearing loss in those 
with SCD. Additionally, a comprehensive middle ear assessment, 
including multifrequency tympanometry and acoustic reflexes, 
would not only identify any middle ear factors contributing to 
the hearing loss, but would help monitor any effects of SCD in 
the middle ear. Finally, while this study examined only children 
with HbSS, there are several other sickle cell hematotypes 
(e.g., HbSC) which should be examined relative to hearing. Do 
different types of SCD predispose a greater risk for hearing 
loss than others? An examination of these factors may provide 
insight into our understanding of the disease process and its 
effects.  
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Table 1 
Mean Pure-tone Audiometric Thresholds and Standard Deviations as a Function of Group, 
Frequency and Ear 
 Frequency (Hz) 
 
Ear 
500 750 1000 1500 2000 3000 4000 6000 8000 
Right          
Sickle Cell 13.5 10.8 9.2 6.8 4.5 7.2 9.2 9.8 6.8 
 (4.9) (5.4) (5.4) (4.7) (5.1) (5.7) (7.5) (9.7) (7.1) 
Control 7.3 6.7 6.3 4.3 2.3 4.7 7.0 5.7 17.0 
 (6.2) (5.2) (6.4) (4.2) (7.3) (7.2) (6.5) (7.0) (7.3) 
Left          
Sickle Cell 13.7 11.3 9.5 5.3 4.7 8.4 10.3 11.0 8.4 
 (5.0) (4.7) (3.3) (5.1) (3.5) (5.3) (6.3) (5.7) (5.5) 
Control 7.0 6.3 4.7 4.3 3.3 7.3 7.7 9.0 12.3 
 (4.1) (5.2) (5.8) (5.3) (5.2) (5.6) (5.6) (6.3) (8.6) 
Note. For the sickle cell group, n = 20; for the control group, n = 15. 
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Table 2 
Percentage of Observed DPOAEs as a Function of Group, Ear, Primary Tone Level and f2 
Frequency 
  f2 Frequency 
 
Level 
 
Ear 
1078 1218 1359 1546 1734 1921 2156 2437 2718 3093 3468 3890 4359 
Low 
Right 
             
 Sickle Cell 80 75 85 90 90 85 85 80 90 90 70 90 65 
 Control 73 80 80 93 80 93 80 80 73 80 73 60 60 
Left              
 Sickle Cell 70 75 65 80 75 85 70 80 75 70 80 70 65 
 Control 93 80 93 93 67 87 93 73 87 80 60 73 60 
              
High 
Right 
             
 Sickle Cell 80 85 100 95 95 95 100 100 100 100 100 95 95 
 Control 100 100 93 100 100 100 87 93 100 100 100 93 93 
Left              
 Sickle Cell 75 80 85 85 95 95 90 95 95 95 95 95 95 
 Control 100 100 100 100 100 93 93 93 93 100 100 93 100 
Note. For the sickle cell group, n = 20; for the control group, n = 15. 
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Table 3 
Summary Table for the Four-Factor Mixed Analysis of Variance Investigating Mean DPOAE 
Amplitude as a Function of Group, Ear, f2 Frequency, and Level 
Source df SS F p 
Group 1 4741.14 6.73 .01* 
Ear 1 4.79 0.24 .63 
Frequency 12 8186.83 34.48 <.0001* 
Level 1 40381.65 2040.73 <.0001* 
Ear x Frequency 12 92.64 0.39 .97 
Level x Ear 1 195.00 9.85 <.0001* 
Level x Frequency 12 1000.73 4.21 <.0001* 
Level x Ear x Frequency 12 162.84 0.69 .77 
Group x Ear 1 0.91 0.05 .83 
Group x Frequency 12 481.30 2.03 .02* 
Group x Level 1 280.77 14.19 <.0001* 
Group x Ear x Frequency 12 108.45 0.46 .94 
Group x Level x Ear 1 13.56 0.69 .41 
Group x Level x Frequency 12 77.15 0.32 .98 
Group x Level x Ear x Frequency 12 56.72 0.24 .99 
Note. *p < .05 
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Continuing Education Questions 
 
1. Sickle cell disease is: 
a. Found only in African-American populations  
b. Hereditary and genetic 
c. Carried by all African-American 
d. All of the above. 
e. None of the above. 
2. Hearing loss in individuals with sickle cell disease is: 
a. Conductive 
b. Cochlear 
c. Central 
d. Conductive or cochlear 
e. Conductive, cochlear or central 
3. According to this study, DPOAE amplitudes in children with 
homozygous sickle cell disease are: 
a. Larger than those in children with normal hemoglobin at low 
L1 and L2 levels 
b. Smaller than those in children with normal hemoglobin at 
low L1 and L2 levels  
c. Larger than those in children with normal hemoglobin at 
high L1 and L2 levels  
d. Larger than those in children with normal hemoglobin at 
both low and high L1 and L2 levels 
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e. Smaller than those in children with normal hemoglobin at 
high L1 and L2 levels 
4. It was thought that children with sickle cell disease would 
have poorer DPOAEs than children with normal hemoglobin 
because: 
a. All people with sickle cell disease have a hearing loss 
b. Children with sickle cell disease are generally smaller 
than children with normal hemoglobin 
c. Cochlear function may be compromised due to impaired 
vascularization 
d. All of the above 
e. None of the above 
5. The larger DPOAE amplitudes in children with SCD than children 
with normal hemoglobin was hypothesized to be a result of: 
a. Reduced efferent suppression of outer hair cell activity 
b. Hyper-responsive outer hair cells due to a mechanism that 
does not involve efferent system dysfunction 
c. Medication regimes that are in some way mediating hyper-
responsive activity in outer hair cell function 
d. Children with SCD may have more efficient middle ear 
backward transmission than children with normal hemoglobin 
e. All of the above 
 
Answer key: 
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1. B 
2. E 
3. D 
4. C 
5. E 
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Figure Captions 
Figure 1. Mean DPOAE amplitudes (dB SPL) as a function of 
group, ear, and f2 frequency at the high-level condition (i.e., 
L1 and L2 of 70 and 60 dB SPL, respectively). The open circles 
and squares represent the right and left ears of the children 
with normal hemoglobin and the and the closed circles and 
squares represent the right and left ears of children with 
sickle cell disease. 
Figure 2. Mean DPOAE amplitudes (dB SPL) as a function of 
group, ear, and f2 frequency at the low-level condition (i.e., L1 
and L2 of 50 and 40 dB SPL, respectively). The open circles and 
squares represent the right and left ears of the children with 
normal hemoglobin and the and the closed circles and squares 
represent the right and left ears of children with sickle cell 
disease. 
Figure 3. Scatter plot representing individual DPOAE 
amplitudes for the children with SCD relative to the 10th and 
90th percentiles of the DPOAE amplitudes from the children with 
the normal hemoglobin for the high primary tone level. 
Figure 4. Scatter plot representing individual DPOAE 
amplitudes for the children with SCD relative to the 10th and 
90th percentiles of the DPOAE amplitudes from the children with 
the normal hemoglobin for the low primary tone level. 
